Background: Kidney dysfunction is a known risk factor for lower-extremity peripheral
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TEXT BACKGROUND AND HYPOTHESES
Peripheral artery disease (PAD), characterized by atherosclerosis of the lower extremities, 1 affects more than 8 million adults in the US, increases the risk of adverse health outcomes, 2 and impacts functional performance. 3 PAD is especially an important complication for those with chronic kidney disease (CKD), particularly at more advanced stages. [4] [5] [6] Indeed, the incidence of PAD is higher than that of myocardial infarction and stroke among dialysis patients. 7 Of note, mildly to moderately reduced kidney function has also been associated with higher risk of PAD in several reports. [8] [9] [10] Since those reports were published, new equations for estimated glomerular filtration rate (eGFR) (e.g., the CKD-EPI equations) or novel filtration markers (e.g., cystatin C and β2-microglobulin (B2M)) have demonstrated stronger associations with cardiovascular events as compared to the more traditional measure of kidney function, creatinine-based eGFR using the MDRD Study equation. [11] [12] [13] [14] [15] [16] However, to our knowledge, those new equations and novel filtration markers have not been exclusively used to assess the risk of incident PAD.
Moreover, patients with kidney dysfunction are prone to have abnormal bone-mineral metabolism, with altered levels of fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), serum calcium, and serum phosphorus. [17] [18] [19] [20] These bone-mineral metabolism (BMM) biomarkers are reported to partially explain excess cardiovascular risk among persons with CKD 17 21-24 but have not been comprehensively evaluated in the context of PAD risk.
Therefore, we comprehensively assessed the association of future risk of PAD with multiple measures of kidney function and BMM using data from a bi-racial communitybased cohort, the Atherosclerosis Risk in Communities (ARIC) study. Our key hypotheses are as follows: 1) novel filtration markers are more strongly associated with PAD risk compared with creatinine-based eGFR; 2) BMM markers attenuate the association between kidney function and PAD risk; 3) and BMM markers are associated with future PAD risk beyond kidney function.
METHODS
Study design and population
The Atherosclerosis Risk in Communities (ARIC) Study is a prospective cohort of and Washington County, MD). The ARIC Study has conducted follow-up visit 2 (1990-1992) , visit 3 (1993-1995) , visit 4 (1996-1998) and visit 5 (2011-2013 Prevalent coronary heart disease was defined as cases adjudicated by physician-panel between visits 1 and 2 in addition to self-reported clinical history and evidence of prior myocardial infarction by electrocardiogram obtained at visit 1. Prevalent stroke was similarly defined by self-reported history at visit 1 and any adjudicated cases between visits 1 and 2. Medications were determined via self-report usage in the past 2 weeks. All serum samples were obtained from participants who were asked to fast for 12 hours before their visit and stored at -80 ℃ according to standardized protocols. Total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured using automated enzymatic procedures, 25 26 and low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation.
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Kidney filtration and bone-mineral metabolism markers eGFR was calculated by the CKD-EPI (CKD Epidemiology Collaboration) 28 -30 equations based on demographical variables such as age, sex and race and either or both filtration markers, serum creatinine and cystatin C (i.e., eGFRcr, eGFRcys, and eGFRcrcys, respectively) . eGFRcr-cys was chosen as the primary kidney filtration marker because it is the best available estimate for measured GFR. 31 Serum creatinine was measured by a modified kinetic Jaffé method, with reliability coefficient of 0.95. Serum cystatin C and B2M were measured by a particle-enhanced immunenephelometric assay using a BNII nephelometer (Siemens Healthcare Diagnostics), with reliability coefficient taking any anti-hypertensive medication), cardiovascular disease (defined as with either prevalent coronary heart disease or stroke) at baseline. Potential effect measure modification was tested using likelihood ratio test by comparing models with and without interaction terms.
All analyses were performed using Stata, version 13.0 (StataCorp LP, College Station, Texas), and statistical significance level was set at 0.05 for all hypothesis testings.
RESULTS
Baseline characteristics
The average age of the participants was 56.9 years old (SD 5.7 years), and 56.5%
(n=7,022) were females, and 75.5% (n=9,388) were whites. As shown in Table 1 , compared with participants who did not develop incident PAD during the follow-up, those who developed PAD were more likely to be older, men, blacks, current smokers, have diabetes and history of stroke and coronary heart disease, higher BMI, SBP, LDL cholesterol level and lower HDL cholesterol level, and take cholesterol-lowering medication and anti-hypertensive medication, while less likely to be highly educated or current drinkers. As shown in Table S1 , kidney filtration markers were moderately to highly correlated to each other (Spearman rank correlation coefficient (|r|) ranges from 0.46 to 0.97) but weakly to BMM markers ((|r| ranges from 0.01 to 0.24) (Table S1 ).
Correlations between BMM markers were also weak (|r| ranges from 0.08 to 0.20).
Associations of eGFRs with incident PAD and CLI
Out of 12,437 participants who were free of PAD at baseline, 471 participants had at least one hospitalization with a discharge code for PAD (crude incidence rate: 2.07 cases/1,000 person-years) during a median follow-up of 21 years, and 171 participants had at least one hospitalization with a discharge code for CLI (crude incidence rate: 0.74 cases/ 1,000 person-years) during a median follow-up of 21 years. Figure 1 shows demographically-adjusted incidence rate of PAD according to eGFRs. Regardless of equations used, incidence rate of PAD increased steadily below eGFR 105 mL/min/1.73 m 2 , with risk gradient of 6-8 fold between eGFR 15 and 105 mL/min/1.73 m 2 . As seen in other cardiovascular outcomes 39 , increased incidence rate of PAD was also observed at high eGFR, when creatinine was used for estimating GFR ( Figure 1A and 1C). This pattern was not necessarily evident for eGFRcys ( Figure 1B ).
With clinical categories of eGFR, we confirmed that the associations with PAD risk remained significant with a stepwise increased risk with decreasing eGFR categories even after accounting for other traditional cardiovascular risk factors (Model 1 in Table 2 ). Specifically, participants with eGFRs <30 mL/min/1.73 m 2 had more than 10-fold higher risk of incident PAD compared to those in the reference group with eGFR ≥90 Table 2 ), but the associations still remained significant. The attenuation was mainly driven by PTH (Table   S2 ). We observed similar associations when CLI was investigated as the outcome of interest ( Table 2 ).
According to the association between eGFRs and incident PAD observed in Figure 1 and Table 2 , to obtain reliable estimates in every subgroup, we assessed whether the HR of PAD for every 15-unit lower eGFR below 105 ml/min/1.73m 2 would differ in subgroups by age, sex, race, ever/never smoking, hypertension, diabetes and prevalent cardiovascular disease status while adjusting for traditional cardiovascular risk factors plus BMM markers (i.e., Model 2) (Table S3) . We found consistent association between low eGFR and incident PAD in all subgroups. We found significant interaction by ever smoking status, diabetes status and hypertension regardless of eGFR equations, but importantly lower eGFR was positively associated with PAD risk in both strata of these subgroups.
Associations of novel filtration markers with incident PAD and CLI
When we contrasted novel filtration markers, cystatin C and B2M with eGFRs using their quartiles (Table 3) , overall, B2M appeared to be most strongly and consistently associated with future PAD risk, with 2.5-2.8 fold higher risk between Q4 vs. Q1. Q3
showed significant results only for B2M, and even its Q2 reached significance for CLI.
As the PAD risk was lowest in Q2 for eGFRs in several models, we also compared the associations with Q2 as reference and confirmed the highest HRs for Q4 of B2M (Table   S4 ). We confirmed similar associations for quartiles of cystatin C and B2M across the subgroups tested (Table S5) .
Associations of BMM markers with incident PAD and CLI
Neither of PTH or calcium demonstrated significant associations with PAD risk in all Models I to III with Q1 as reference ( [50] [51] [52] [53] Similar to other subtypes of cardiovascular outcomes, we observed that novel filtration markers, cystatin C and B2M, are more strongly associated with PAD compared to creatinine-based eGFR. 16 As discussed previously, there may be kidney-related and nonkidney elements behind this observation. 54 Specifically, cystatin C and B2M may be superior to serum creatinine as filtration markers and indeed are less affected by diet and muscle mass. 31 In terms of non-kidney elements, cystatin C and B2M are known to be linked to inflammation, which may contribute to their strong associations with atherosclerotic disease. In addition, B2M has been shown to be indicative of amyloid deposition and aggregation in the vessel wall that may contribute to atherosclerosis process. 55 56 Of note, in a proteomic profiling study, out of ~1,600 protein peaks assessed, B2M was found to be most robustly associated with PAD. 57 We did not observe consistent associations of multiple BMM markers with PAD risk.
The results for PTH are not necessarily surprising as it was not strongly associated with several cardiovascular diseases in a previous report from the ARIC Study. 33 FGF-23 has been shown to be associated with other subtypes of cardiovascular disease in some studies, 58 59 but its association with PAD in our study was no longer significant once adjusting for kidney function. Of those BMM markers, phosphorus was the only significant one associated with PAD even after accounting for kidney function. Although we are not completely sure about the mechanisms behind this link, our findings are in line with a previous study showing the relationship between phosphorus and the risk of composite cardiovascular outcomes including coronary heart disease, stroke, PAD, and heart failure. 49 Unfortunately, that previous study did not report specific results for PAD.
Serum phosphorus is known to induce vascular calcification through mineralization of the extracellular matrix 60 . High phosphorus levels would also inhibit 1,25-dihydroxy vitamin D synthesis 24 61 , which might subsequently increase vascular calcification.
Nonetheless, future investigations of the mechanisms linking phosphorus to the development of PAD are warranted.
Our study results may have some clinical and public health implications. These results highlight that reduced kidney function, even at mild to moderate stage, is a risk factor for PAD and CLI, independently of well-known traditional cardiovascular risk factors.
Besides, novel filtration markers may lead to better risk stratification of future PAD.
Given a possible role for phosphorus in the pathophysiology of PAD suggested in our study, future investigations would be warranted regarding whether controlling serum phosphorus levels could result in reduction of PAD risk. This may be important since there are no established treatments to recover kidney function, but phosphate-binding agents are clinically available. In this context, it may be important to recognize that high phosphorus diet also contributes significantly to serum phosphorus levels. Note: a. The unit for eGFRs is mL/min/1.73 m 2 . HRs were calculated from linear combinations of coefficients in the model with interaction terms based on model 2, and p-value was obtained from likelihood ratio test comparing models with and without the interaction term. Specifically, (1) when stratifying by age, covariates in the model included main effects of the binary age category and both of the two slopes as well as their interactions, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (2) when stratifying by gender, covariates in the model included main effects of gender and both of the two slopes as well as their interactions, age, race, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (3) when stratifying by race, covariates in the model included main effects of race and both of the two slopes as well as their interactions, age, gender, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (4) when stratifying by ever smoking, covariates in the model included main effects of binary smoking category (ever vs. never smoking) and both of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, BMI, alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (5) when stratifying by diabetes status, covariates in the model included main effects of binary indicator for diabetes and both of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-cholesterol medication, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (6) when stratifying by hypertension status, covariates in the model included main effects of hypertension and each of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; (7) when stratifying by prevalent CVD, covariates in the model included main effects of prevalent CVD and each of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, systolic blood pressure, antihypertensive medication, lowering-cholesterol medication, diabetes, plus FGF23, PTH, calcium and phosphorus. 
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